Yes, thank you, Madam Chair. Madam Chair, the office, I believe, is fully staffed or almost fully staffed at this point. And they have -- they have been looking, as I think I mentioned earlier, at cost containment. And so one thing that they've looked at as an example of that is reciprocal billing. It turns out that we were not issuing all the invoices that we could to other jurisdictions for caring for their residents and so that's something that we have paid more attention to in order to ensure that we're getting all the revenue that is properly owed to us.

Another example is going into product listing agreements with pharmaceutical companies to take advantage of discounts they provide on bulk orders. And that has saved us quite a good sum of money, in the millions.

We've also introduced a biosimilar initiative where we fund preferentially biosimilar or generic drugs rather than brand name drugs if the formulation is exactly the same.

So those are some of the things that we've tried to do the cost containment piece of this work. But this is long-term work. We won't be on top of all the ways that we can save money even in the next fiscal year. And this is going to blend together with the government renewal initiative which, you know, we've now done an inventory of all of our programs for. And so I can see that in the next year we're going to be paying more attention to that and what value for money we get for our different programs. So there are initiatives underway that acknowledge the situation that we're in and remedies to it. Thank you.